Hauptseite > Publikationsdatenbank > Rituximab in non-systemic vasculitic neuropathy: a single-center experience > print

001     1027019
005     20250204113901.0
024 7 _ |a 10.1007/s00415-024-12378-1
|2 doi
024 7 _ |a 0367-004X
|2 ISSN
024 7 _ |a 0012-1037
|2 ISSN
024 7 _ |a 0340-5354
|2 ISSN
024 7 _ |a 1432-1459
|2 ISSN
024 7 _ |a 10.34734/FZJ-2024-03585
|2 datacite_doi
024 7 _ |a 38656623
|2 pmid
024 7 _ |a WOS:001208272700002
|2 WOS
037 _ _ |a FZJ-2024-03585
082 _ _ |a 610
100 1 _ |a Kohle, Felix
|0 0000-0002-4429-0367
|b 0
|e Corresponding author
245 _ _ |a Rituximab in non-systemic vasculitic neuropathy: a single-center experience
260 _ _ |a Heidelberg
|c 2024
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1721216946_1237
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Funding Open Access funding enabled and organized by Projekt DEAL. FK was supported by the Cologne Clinician Scientist Program (CCSP)/Faculty of Medicine/University of Cologne. Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (Project No. 413543196).
520 _ _ |a Objectives This case series reports clinical features and outcome of four patients with non-systemic vasculitic neuropathy(NSVN) treated with the anti-CD20 agent rituximab.Methods Clinical, electrophysiological and biopsy data were retrospectively obtained and evaluated. Only patients withpathological definite or probable NSVN were included. Extensive clinical and laboratory work-up excluded systemic vasculitis.Follow-up data for at least 12 months and up to five years is provided. Outcome of the patients was assessed usingthe MRC-Sum Score, Prineas Score and Neurological Symptom Score.Results Two of four patients treated with rituximab achieved disease remission and one patient remained stable under anti-CD20 therapy after a required treatment switch due to toxic side effects of cyclophosphamide. One patient deteriorated underrituximab induction. Rituximab was well tolerated in all patients.Discussion Anti-CD20 therapy might be an alternative in NSVN patients requiring further treatment escalation or treatmentswitch due to side effects of corticosteroids or cyclophosphamide.
536 _ _ |a 5251 - Multilevel Brain Organization and Variability (POF4-525)
|0 G:(DE-HGF)POF4-5251
|c POF4-525
|f POF IV
|x 0
536 _ _ |a DFG project 413543196 - Kölner Clinician Scientist Programm (413543196)
|0 G:(GEPRIS)413543196
|c 413543196
|x 1
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Wunderlich, Gilbert
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Fink, Gereon R.
|0 P:(DE-Juel1)131720
|b 2
700 1 _ |a Schroeter, Michael
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Lehmann, Helmar C.
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Schneider, Christian
|0 P:(DE-HGF)0
|b 5
773 _ _ |a 10.1007/s00415-024-12378-1
|g Vol. 271, no. 7, p. 4406 - 4411
|0 PERI:(DE-600)1421299-7
|n 7
|p 4406 - 4411
|t Journal of neurology
|v 271
|y 2024
|x 0367-004X
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/1027019/files/s00415-024-12378-1.pdf
856 4 _ |y OpenAccess
|x icon
|u https://juser.fz-juelich.de/record/1027019/files/s00415-024-12378-1.gif?subformat=icon
856 4 _ |y OpenAccess
|x icon-1440
|u https://juser.fz-juelich.de/record/1027019/files/s00415-024-12378-1.jpg?subformat=icon-1440
856 4 _ |y OpenAccess
|x icon-180
|u https://juser.fz-juelich.de/record/1027019/files/s00415-024-12378-1.jpg?subformat=icon-180
856 4 _ |y OpenAccess
|x icon-640
|u https://juser.fz-juelich.de/record/1027019/files/s00415-024-12378-1.jpg?subformat=icon-640
909 C O |o oai:juser.fz-juelich.de:1027019
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)131720
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5251
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-10
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-10
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROL : 2022
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-10
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-10
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J NEUROL : 2022
|d 2024-12-10
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21